Sone Capital Management LLC Invests $18.07 Million in The Cooper Companies, Inc. (NASDAQ:COO)

Sone Capital Management LLC bought a new stake in shares of The Cooper Companies, Inc. (NASDAQ:COO) during the 4th quarter, according to its most recent filing with the SEC. The firm bought 196,565 shares of the medical device company’s stock, valued at approximately $18,070,000. Cooper Companies accounts for 2.3% of Sone Capital Management LLC’s holdings, making the stock its 7th biggest position. Sone Capital Management LLC owned 0.10% of Cooper Companies as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of COO. Barclays PLC boosted its position in Cooper Companies by 0.7% in the 3rd quarter. Barclays PLC now owns 462,947 shares of the medical device company’s stock valued at $51,082,000 after buying an additional 3,070 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Cooper Companies by 13.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,930,022 shares of the medical device company’s stock valued at $543,979,000 after purchasing an additional 573,908 shares in the last quarter. Park Avenue Securities LLC increased its holdings in Cooper Companies by 4.9% during the 4th quarter. Park Avenue Securities LLC now owns 8,087 shares of the medical device company’s stock worth $743,000 after purchasing an additional 380 shares during the last quarter. Avanza Fonder AB bought a new stake in shares of Cooper Companies in the fourth quarter worth $2,018,000. Finally, HB Wealth Management LLC raised its holdings in Cooper Companies by 24.1% in the fourth quarter. HB Wealth Management LLC now owns 2,913 shares of the medical device company’s stock valued at $268,000 after acquiring an additional 565 shares in the last quarter. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on COO. Needham & Company LLC reissued a “hold” rating on shares of Cooper Companies in a research report on Friday, March 7th. Robert W. Baird decreased their price objective on shares of Cooper Companies from $117.00 to $107.00 and set an “outperform” rating for the company in a report on Friday, March 7th. Citigroup decreased their price target on shares of Cooper Companies from $115.00 to $110.00 and set a “buy” rating for the company in a report on Friday, March 7th. BNP Paribas raised shares of Cooper Companies to a “hold” rating in a report on Thursday, March 13th. Finally, Stifel Nicolaus lowered their target price on Cooper Companies from $115.00 to $105.00 and set a “buy” rating for the company in a report on Friday, March 7th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $110.25.

Cooper Companies Trading Up 1.8%

Shares of NASDAQ:COO opened at $82.92 on Monday. The Cooper Companies, Inc. has a twelve month low of $69.81 and a twelve month high of $112.38. The company has a current ratio of 1.91, a quick ratio of 1.12 and a debt-to-equity ratio of 0.32. The firm has a market cap of $16.58 billion, a P/E ratio of 42.52, a P/E/G ratio of 2.25 and a beta of 1.08. The company has a 50 day moving average of $80.19 and a 200-day moving average of $90.00.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings data on Thursday, March 6th. The medical device company reported $0.92 EPS for the quarter, hitting analysts’ consensus estimates of $0.92. The company had revenue of $964.70 million for the quarter, compared to the consensus estimate of $981.25 million. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. As a group, analysts anticipate that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.